Matching articles for "page 49"
Issue 1341 · June 28, 2010
Preservation of Ovarian Function During Chemotherapy

Chemotherapy can result in premature menopause and infertility in young women. Pretreatment fertility counseling followed by appropriate action may prevent some of these undesirable consequences.

Med Lett Drugs Ther. 2010 Jun 28; 52(1341):49-50
Chemotherapy can result in premature menopause and infertility in young women. Pretreatment fertility counseling followed by appropriate action may prevent some of these undesirable consequences.
Issue 1341 · June 28, 2010 Free
In Brief: Only The Name Remains The Same

A Medical Letter subscriber was surprised to discover that a new Citracal product contained not only calcium citrate, but also calcium carbonate. Citracal Plus Bone Density Builder actually contains more…

Med Lett Drugs Ther. 2010 Jun 28; 52(1341):49
A Medical Letter subscriber was surprised to discover that a new Citracal product contained not only calcium citrate, but also calcium carbonate. Citracal Plus Bone Density Builder actually contains more calcium carbonate per tablet than calcium citrate (240 mg vs. 60 mg). Another Citracal product, Citracal Plus Heart Health , also contains more calcium carbonate than calcium citrate. Many clinicians prefer calcium citrate because it can be taken with or without food, while calcium carbonate must be taken with food for optimal absorption. Other familiar over-the-counter (OTC) names also contain some surprises among their ingredients, as shown in the table below. >Many well-known brand-name OTC products no longer contain only or necessarily any of their original ingredients. Download: U.S. English
Issue 1315 · June 29, 2009 Free
In Brief: Biennial IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis

The FDA, which had previously approved intravenous (IV) administration of 5 mg of zoledronic acid ( Reclast – Novartis) once a year for treatment of postmenopausal osteoporosis (Med Lett Drugs Ther 2007;…

Med Lett Drugs Ther. 2009 Jun 29; 51(1315):49
The FDA, which had previously approved intravenous (IV) administration of 5 mg of zoledronic acid ( Reclast – Novartis) once a year for treatment of postmenopausal osteoporosis (Med Lett Drugs Ther 2007; 49:89) , has now approved the same dose for use once every 2 years to prevent osteoporosis in postmenopausal women with osteopenia. Clinical Studies – In an unpublished study summarized in the package insert, 224 women with osteopenia ≤5 years after menopause were given an IV infusion of zoledronic acid 5 mg or placebo; 2 years later, total hip bone mineral density (BMD) had increased by 2.6% with the drug and decreased by 2.1% with placebo. Among 357 osteopenic women >5 years after menopause, hip BMD 2 years after one IV dose of zoledronic acid increased by 2.1% and decreased by 1.0% with placebo. Both of these differences from placebo were statistically significant. Similarly significant increases occurred in vertebral BMD. No data are available on the incidence of hip or vertebral fractures in these women, but zoledronic acid once a year for treatment of osteoporosis has been shown to decrease the incidence of such fractures. Adverse Effects — An acute-phase reaction including fever, flu-like symptoms, headache, arthralgia and myalgia can occur with IV administration of zoledronic acid; symptoms usually subside within a few days. Renal damage can occur after a single dose, especially with concomitant use of other nephrotoxic drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs). Jaw osteonecrosis has occurred rarely. Whether long-term use of bisphosphonates, which interfere with bone remodeling, could increase the incidence of long-bone fractures remains to be established. None of these events, except for acutephase reactions, occurred during the clinical trial, according to the manufacturer. Cost – The cost of one 5-mg injection of Reclast is about $1200 for the drug alone. Download: U.S. English
Issue 1315 · June 29, 2009
A Medical Food for Alzheimer's Disease

Axona (Accera) , a "medical food" containing a proprietary formulation of medium-chain triglycerides (>95% caprylic triglyceride), is currently being marketed for the "clinical dietary management of the…

Med Lett Drugs Ther. 2009 Jun 29; 51(1315):49-50
Axona (Accera) , a "medical food" containing a proprietary formulation of medium-chain triglycerides (>95% caprylic triglyceride), is currently being marketed for the "clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease."
Issue 1289 · June 30, 2008
Finasteride for Prevention of Prostate Cancer

Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to…

Med Lett Drugs Ther. 2008 Jun 30; 50(1289):49-50
Patients are asking physicians about an article on the front page of the June 15th New York Times, in which some prostate cancer experts were quoted as suggesting that men 55 and older might be well advised to take finasteride ( Proscar , and others) to prevent prostate cancer.
Issue 1289 · June 30, 2008 Free
In Brief: Intensive Glucose Lowering in Type 2 Diabetes

The goal for drug therapy of type 2 diabetes is achieving and maintaining a near-normal glycated hemoglobin (HbA 1C ) concentration without inducing hypoglycemia; the target has generally been an HbA 1C of…

Med Lett Drugs Ther. 2008 Jun 30; 50(1289):49
The goal for drug therapy of type 2 diabetes is achieving and maintaining a near-normal glycated hemoglobin (HbA 1C ) concentration without inducing hypoglycemia; the target has generally been an HbA 1C of 6.5-7.0% or lower. Whether treating to this level prevents macrovascular (cardiovascular) events has been unclear. Now, 2 large randomized, double-blind trials in patients with long-standing diabetes and at high risk for cardiovascular disease have found no decrease in macrovascular events with intensive glucose control. The ACCORD trial in about 10,000 patients found that patients intensively treated with anti-hyperglycemic drugs, including frequent use of thiazolidinediones, mostly rosiglitazone (Avandia) , and insulin, with an HbA 1C target of 6.0% (actual median HbA 1C 6.4%) did not obtain a significant reduction in major cardiovascular events (the primary endpoint) over a period of 3.5 years. The trial was stopped early because of an unexpected increase in all-cause mortality (257 deaths vs. 203) in intensively treated patients compared to patients with an HbA 1C target of 7.0-7.9% (actual median HbA 1C 7.5%). The etiology of the higher mortality is unclear. 1 The ADVANCE trial in about 11,000 similar patients treated to an HbA 1C target of 6.5% with a sulfonylurea-based regimen, and infrequent use of thiazolidinediones, also found no decrease in macrovascular events, but no increase in all-cause mortality. 2 Whether intensive glycemic control would reduce macrovascular events in patients at lower risk has not been established. 1. The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545. 2. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560. Download U.S. English
Issue 1263 · June 18, 2007
Treatment of Lyme Disease

Most cases of Lyme disease in North America occur between May and September. In 2005, 12 states (CT, DE, ME, MD, MA, MI, NH, NJ, NY, PA, VA, WI) reported about 95% of all the Lyme disease in the US, but some…

Med Lett Drugs Ther. 2007 Jun 18; 49(1263):49-51
Most cases of Lyme disease in North America occur between May and September. In 2005, 12 states (CT, DE, ME, MD, MA, MI, NH, NJ, NY, PA, VA, WI) reported about 95% of all the Lyme disease in the US, but some cases occurred in all states except AR, CO, HI, MS, MT and OK. New guidelines for treatment of Lyme disease have been published.